



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/24, 37/26	A1	(11) International Publication Number: WO 90/14838 (43) International Publication Date: 13 December 1990 (13.12.90)
(21) International Application Number: PCT/US90/03166 (22) International Filing Date: 5 June 1990 (05.06.90) (30) Priority data: 361,595 5 June 1989 (05.06.89) US (71) Applicant: CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). (72) Inventors: LEWIS, Michael, E. ; 23 Bills Way, Landenberg, PA 19350 (US). KAUER, James, C. ; 605 Willow Glen Road, Kennette Square, PA 19348 (US). SMITH, Kevih, R. ; 240 Moore Road, Downingtown, PA 19335 (US). CALLISON, Kathleen, V. ; 121 Plymouth Place, Merchantville, NJ 08109 (US). BALDINO, Frank, Jr. ; 13 Eden Dell, Landenberg, PA 19350 (US).		(74) Agent: FRENCH, Timothy, A.; Fish & Richardson, One Financial Center, Suite 2500, Boston, MA 02111-2658 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS (57) Abstract A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; or a functional derivative of IGF-II, provided that if IGF-I or IGF-II is administered, NGF or a functional derivative of NGF is also administered. <div data-bbox="1153 1753 1437 1858" style="text-align: right; border: 1px solid black; padding: 5px; margin-top: 20px;">S/N 08/571,802 B2</div>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

- 1 -

TREATING DISORDERS BY APPLICATION OF
INSULIN-LIKE GROWTH FACTORS AND ANALOGS

BACKGROUND OF THE INVENTION

This application is a continuation-in-part of Lewis et al. USSN 361, 595 filed on June 6, 1989.

The present invention relates to therapeutic polypeptides useful, e.g., for the treatment of neurological and other disorders.

Insulin-like growth factors (IGFs) have been identified in various animal species as polypeptides that act to stimulate growth of cells in a variety of tissues (see Baxter et al., Comp. Biochem. Physiol. 91B:229-235 (1988); and Daughaday et al., Endocrine Rev. 10:68-91 (1989) for reviews), particularly during development (see D'Ercole, J. Devel. Physiol. 9:481-495 (1987) for review). The IGFs, each of which has a molecular weight of about 7,500 daltons, are chemically related to human proinsulin: i.e. they possess A and B domains that (1) are highly homologous to the corresponding domains of proinsulin, and (2) are connected by a smaller and unrelated C domain. A carboxyl-terminal extension, the D domain, is also present in IGFs but is not found in proinsulin.

Certain polypeptide fragments of the IGFs have proven to be useful as antigens to raise antibodies specific for each of the IGFs (see, e.g., Japanese Patent Application No. 59065058; Hintz and Liu, J. Clin. Endocr. Metab. 54:442-446 (1982); Hintz et al., Horm. Metab. Res. 20:344-347 (1988)). Using labelled IGF-specific antibodies as a probe, IGF-I and IGF-II (sometimes respectively termed "somatomedin C" and "somatomedin A") have been found in a variety of tissues, including the mammalian central nervous system(CNS); the presence in the CNS of mRNAs encoding these polypeptides

- 2 -

suggests local synthesis in the CNS (see Baskin et al., TINS 11:107-111 (1988) for review). In addition, IGF-III (or "brain IGF"), a truncated form of IGF-I lacking the latter protein's three N-terminal amino acid residues, has been found in fetal and adult human brain (Sara et al., Proc. Natl. Acad. Sci. USA 83:4904-4907 (1986), as well as in colostrum (Francis et al., Biochem. J. 251:95-103 (1988)). Two different IGF receptors have been identified in the adult human CNS (Baskin et al., 1988), including in the brain (Sara et al., Neurosci. Let. 34:39-44 (1982)). In addition, European Patent Application No. 86850417.6 describes evidence for a third type of IGF receptor located in human fetal membranes. Complicating research in this area are (1) evidence that the insulin receptor of brain membranes recognizes not only insulin but also the IGFs; (2) the finding that one of the two types of adult IGF receptors exhibits some affinity for insulin as well as for both IGF-I and II, and (3) current uncertainty as to the physiological significance of binding of IGF-II to the second type of adult IGF receptor (Baskin et al., 1988).

IGF-I and IGF-II appear to exert a stimulatory effect on development or proliferation of a wide range of susceptible cell types (see Daughaday et al., 1989 for review). Treatment with the IGFs or with certain polypeptide fragments thereof has been variously suggested as a bone repair and replacement therapy (European Patent Application No. 88303855.6), as a means to counteract certain harmful side effects of carcinostatic drugs (Japanese Patent Application No. 63196524), and as a way to increase lactation and meat production in cattle and other farm animals (Larsen et al., U.S. Patent No. 4,783,524). Each of the IGFs also appears to enhance the survival, proliferation and/or neurite outgrowth of cultured embryonic neurons (which, unlike mature neurons, have not yet lost their ability to undergo cell division) from various parts of the CNS (Aizenman et al., Brain Res. 406:32-42 (1987);

- 3 -

Fellows et al., Soc. Neurosci. Abstr. 13:1615 (1987); Onifer et al., Soc. Neurosci. Abstr. 13:1615 (1987); European Patent Application No. 86850417.6, and from the peripheral nervous system (Bothwell, J. Neurosci. Res. 8:225-231 (1982);

5 Recio-Pinto et al., J. Neurosci. 6:1211-1219 (1986)). In addition, the IGFs have been shown to affect the development of undifferentiated neural cells: human neuroblastoma tumor cells were shown to respond to added IGFs by extending neurites (Recio-Pinto and Ishii, J. Neurosci. Res. 19:312-320 (1988)) as
10 well as by undergoing mitosis (Mattson et al., J. Cell Biol. 102:1949-54 (1986)). As the induction of the enzyme ornithine decarboxylase has been shown to correlate with the stimulation of mitotic activity of these cells, an assay for cell proliferation has been developed based upon measuring the level
15 of activity of this enzyme (Mattsson et al., 1986).

Developing forebrain cholinergic neurons (cultured rat septal neurons) are sensitive to a variety of growth factors in vitro. Addition of nerve growth factor (NGF) to the culture medium increases the number of cells positive for the
20 expression of transmitter-specific enzymes (acetyl choline esterase (AChE) and choline acetyl transferase (ChAT)) (Hartikka and Hefti, J. Neuroscience 8:2967-2985 (1988)). Thyroid hormone also increases the level of ChAT in cultured septal neurons and thyroid hormone in combination with NGF
25 results in a stimulation of ChAT activity much greater than the sum of the effects of individual addition of these two substances (Hayashi and Patel, Dev. Brain Res. 36:109-120 (1987)). IGF-I, IGF-II, and insulin also induce ChAT activity in cultured septal neurons (Knusel et al., J. of Neuroscience
30 10:558-570 (1990)). When NGF and insulin are both added to the culture medium the effect on ChAT activity is additive, but the effects of IGF-I or IGF-II in combination with insulin are not additive (Knusel et al., 1990).

- 4 -

In vivo studies also support the hypothesis that the IGFs play a role in development and differentiation of the immature peripheral and central nervous systems (Sara et al., J. Dev. Physiol. 1:343-350 (1979); Philipps et al., Pediatr. Res. 23:298-305 (1988); Sara et al., Prog. Brain Res. 73:87-99 (1988)), although the physiological nature of this role remains uncertain. Once the neuronal cells of the CNS reach maturity, they do not undergo further cell division.

Neurotrophic factors other than the IGFs have been proposed as a potential means of enhancing neuronal survival, for example as a treatment for the neurodegenerative diseases amyotrophic lateral sclerosis (using skeletal muscle-derived proteins having apparent molecular weights in the 20,000-22,000 dalton and 16,000-18,000 dalton ranges: PCT Application No. PCT/US88/01393), and Alzheimer's disease (using phosphoethanolamine: PCT Application No. PCT/US88/01693). Sara et al., although finding a "significant elevation" in serum and cerebrospinal fluid somatomedin (IGF) levels in patients suffering from Alzheimer's disease compared to normal controls, nevertheless conclude:

Whether somatomedins play a casual (sic) role in the etiology of the dementia disorders of the Alzheimer type remains to be determined. However, since somatomedins stimulate the uptake of amino acids into brain tissue, their administration may provide beneficial therapeutic effects. Finally, the fall in somatomedins observed in normal elderly patients raises the general question of their role in cell aging. (citation omitted; Sara et al., Neurobiol. Aging 3:117-120, 119 (1982)).

In a report that IGF-I, but not IGF-II, stimulates the immediate (i.e. within 20 min.) release of acetylcholine from slices of adult rat brain, a process thought to be related to transitorily increased neurotransmission of acetylcholine rather than to increased cholinergic enzyme activity, Nilsson et al., Neurosci. Lett. 88:221-226, 221, 224 (1988), point out that

- 5 -

[One] of the major deficits in Alzheimer's disease concerns the cholinergic system of the brain, where a reduced synthesis and release of [acetylcholine] has been found....It is of considerable importance to further investigate the role of IGFs in neurodegenerative disorders such as Alzheimer's disease... (citations omitted).

Using antibody specific for IGF-I to detect an increase in the presence of IGF-I in injured peripheral nerves, notably in the non-neuronal cells named "Schwann cells", Hansson et al., Acta Physiol. Scand. 132:35-41, 38, 40 (1988), suggest that

Thus, increased IGF-I immunoreactivity is observed in regenerating peripheral nerves after any injury and seems to form part of a general reaction pattern, most evident in the Schwann cells. Our ultrastructural studies have revealed that the Schwann cells undergo hypertrophy after vibration trauma, and show signs of activation, i.e. the granular endoplasmic reticulum and Golgi complex increased in extent. We thus interpret the increase in IGF-I immunoreactivity in the Schwann cells, documented in this study on vibration-exposed nerves, as part of a transient, reactive response beneficial for the early stages of repair processes....We consider the increase in IGF-I immunoreactivity to reflect mainly the initial reactions in a chain of events resulting in repair of the injured tissue or organ [although this increase] may be interpreted to reflect disturbed axoplasmic transport [of IGF-I molecules], due in part to the diminution of microtubules reported to occur after vibration exposure. (citation omitted)

Further, Sjoberg et al., Brain Res. 485:102-108 (1989), have found that local administration of IGF-I to an injured peripheral nerve stimulates regeneration of the nerve as well as proliferation of associated non-neuronal cells.

Several methods have been employed to decrease the susceptibility of polypeptides to degradation by peptidases, including, e.g., substitution of D-isomers for the naturally-occurring L-amino acid residues in the polypeptide

- 6 -

(Coy et al., Biochem. Biophys. Res. Commun. 73:632-8 (1976)). Where the polypeptide is intended for use as a therapeutic for disorders of the CNS, an additional problem must be addressed: overcoming the so-called "blood-brain barrier," the brain capillary wall structure that effectively screens out all but selected categories of molecules present in the blood, preventing their passage into the brain. While the blood-brain barrier may be effectively bypassed by direct infusion of the polypeptide into the brain, the search for a more practical method has focused on enhancing transport of the polypeptide of interest across the blood-brain barrier, such as by making the polypeptide more lipophilic, by conjugating the polypeptide of interest to a molecule which is naturally transported across the barrier, or by reducing the overall length of the polypeptide chain (Pardridge, Endocrine Reviews 7:314-330 (1986); U.S. Patent No. 4,801,575.

SUMMARY OF THE INVENTION

In general, the invention features a method of enhancing the survival of neuronal cells at risk of death, preferably non-mitotic neuronal cells and/or cholinergic neuronal cells, in a mammal, preferably in the context of a therapeutic treatment of neuronal tissues which are suffering from the effects of aging, of injury, or of a disease e.g., Alzheimer's disease, stroke, epilepsy, amyotrophic lateral sclerosis, or Parkinson's disease, by administering to the mammal an effective amount at least one of the following: IGF-I, a functional derivative of IGF-I, IGF-II, or a functional derivative of IGF-II, with or without the administration of an effective amount of NGF or a functional derivative thereof, provided that, if IGF-I or IGF-II is administered, NGF or a functional derivative thereof is administered.

- 7 -

The invention also features a method of enhancing the survival of neuronal cells at risk of death, preferably non-mitotic neuronal cells and/or cholinergic neuronal cells, in a mammal, preferably in the context of a therapeutic treatment of neuronal tissues which are suffering from the effects of aging, of injury, or of a disease, e.g., Alzheimer's disease, stroke, epilepsy, amyotrophic lateral sclerosis, or Parkinson's disease, by treating said mammal with a first treatment including administration of a cell survival promoting amount of a growth factor, e.g., IGF-1 or IGF-2, or a functional derivative of the growth factor (e.g., a fragment, analog, or analog of a fragment of the first growth factor), alone, or in a biologically active combination with another such growth factor or functional derivative, and then treating said mammal with a second treatment including administration of a nerve transmitter increasing amount of a transmitter enhancer e.g., NGF, or a functional derivative of the transmitter enhancer (e.g., a fragment, analog, or analog of a fragment of the transmitter enhancer). In preferred embodiments fragments, analogs, or analogs of fragments of IGF-I, IGF-II, or NGF are administered.

The invention also features a method of enhancing the cholinergic activity (i.e., acetylcholine-synthesizing capacity) of cholinergic neuronal cells in a mammal, preferably non-mitotic neuronal cells, and preferably in the context of a therapeutic treatment of neuronal tissues which are suffering from the effects of aging, of injury, or of a disease, e.g., Alzheimer's disease, stroke, epilepsy, amyotrophic lateral sclerosis, or Parkinson's disease, by administering to the mammal an effective amount of one or more of the following: IGF-I, IGF-II, a functional derivative of IGF-I, or a functional derivative of IGF-II (preferably administering a fragment of IGF-I or IGF-II or, alternatively, administering an analog of IGF-I, of IGF-II, or an analog of a

- 8 -

fragment of IGF-I or IGF-II), with or without the administration of an effective amount of NGF or a functional derivative thereof, provided that if IGF-I or IGF-II is administered, NGF or a functional derivative thereof is also administered.

The invention also features a method of enhancing the cholinergic activity (i.e., acetylcholine-synthesizing capacity) of cholinergic neuronal cells in a mammal, preferably non-mitotic neuronal cells, and preferably in the context of a therapeutic treatment of neuronal tissues which are suffering from the effects of aging, of injury, or of a disease, e.g., Alzheimer's disease, stroke, epilepsy, amyotrophic lateral sclerosis, or Parkinson's disease, by treating said mammal with a first treatment including administration of a cell survival promoting amount of a growth factor, e.g., IGF-I or IGF-II, or a functional derivative of the growth factor (e.g., a fragment, analog, or analog of a fragment), along, or in a biologically active combination with another such growth factor or functional derivative, and then treating said mammal with a second treatment including an administration of a nerve transmitter increasing amount of a transmitter enhancer, e.g., a factor that increases the level of a transmitter specific enzyme in the cell, e.g., NGF, or a functional derivative of a transmitter enhancer (e.g., a fragment, analog, or analog of a fragment).

Another method of the invention features treating a head or spinal cord injury of a mammal, or a disease condition of a mammal, e.g., stroke, epilepsy, age-related neuronal loss, amyotrophic lateral sclerosis, Alzheimer's disease, or Parkinson's disease, by (1), administering to the mammal an effective amount of at least one of the following substances: IGF-I, a functional derivative of IGF-I, IGF-II, or a functional derivative of IGF-II, with or without the administration of NGF or a functional derivative thereof, or by

- 9 -

(2), treating said mammal with a first treatment including administration of a cell survival promoting amount of one or more of a first group of substances, e.g., IGF-I, a functional derivative of IGF-I, IGF-II, or a functional derivative of IGF-II, and then treating said mammal with a second treatment including administration of a nerve transmitter increasing amount of a transmitter enhancer or a functional derivative thereof, e.g., NGF or a functional derivative thereof.

The invention also features a method of modifying a ligand, preferably a neuroactive polypeptide, capable of binding to a receptor located on a cell surface, by first binding the ligand to a preparation of said receptor, then performing the modification procedure (preferably cationization, glycosylation, or increasing the lipophilicity of the polypeptide), and then releasing the modified ligand from the receptor.

Polypeptides administered in methods of the invention may be chemically modified in such a way as to increase the transport of the polypeptide across the blood-brain barrier, e.g., by modifications of the polypeptide that increase lipophilicity, alter glycosylation, or increase net positive charge.

Embodiments of the invention include the administration of more than one neuroactive polypeptide. In preferred embodiments the combined desired effect of administration of the polypeptides is additive, and in more preferred embodiments the effect is synergistic.

In other preferred embodiments, where a fragment of IGF-II is administered, IGF-II(54-67) is the preferred IGF-II fragment.

The invention also features a composition including a first component taken from the group of, purified IGF-I, a purified functional derivative of IGF I, purified IGF-II, or a purified functional derivative of IGF II, and a second

- 10 -

component taken from the group of, purified NGF, or a purified functional derivative of NGF. Purified means that the substance is of 95% or greater (by weight) purity, i.e., that it is substantially free of proteins, lipids, and carbohydrates with which it is naturally associated.

The methods of the invention use IGF-I, IGF-II, functional derivatives of IGF-I and of IGF-II, combinations thereof, and combinations thereof which also include NGF or functional derivatives of NGF to enhance the survival rate and/or the cholinergic activity of mammalian cells at increased risk of death due to some factor such as disease, injury, or natural aging processes, or where stimulation of cholinergic activity could have a beneficial effect on the mammal's condition. Some of the functional derivatives utilized by the method of the invention are known; others may be discovered by applying the routine methods disclosed herein.

Methods (and compositions) of the invention, e.g., the joint administration of IGF-I and NGF, enhance the survival and neurotransmitter-synthesizing capacity of cholinergic neurons in a previously unknown, complimentary manner.

Survival of a treated neuronal cell denotes maintenance of the cell's viability to an extent greater than that of untreated control cells. Since the preponderance of neuronal cells of the mature CNS are commonly believed to be incapable of cell division, the ability of an agent to promote the survival of such cells maybe measured by an assay indicative of cellular trophic response, such as the ornithine decarboxylase assay disclosed herein. Alternatively, one can utilize any other assay which reproducibly indicates relative numbers of surviving cells, such as directly counting cells which stain as viable cells or which possess other characteristics of viable neurons, or assaying incorporation of appropriate labelled precursors into mRNA or prot in. Where the effect of an added growth factor, functional derivatives,

- 11 -

or a combination of growth factors and/or functional derivatives on the functioning of cholinergic neurons is of particular interest, an alternative assay which measures that functioning, such as the choline acetyltransferase or acetyl choline esterase assays disclosed herein, may be utilized.

Any of these approaches may be adapted to test the effect of treatment with growth factors, functional derivatives, or combinations of growth factors and/or functional derivatives on particular subsets of neurons known to be vulnerable in specific degenerative diseases, such as spinal cord cholinergic neurons in amyotrophic lateral sclerosis. A preliminary screen for polypeptides which bind to the IGF or NGF receptors may first be employed to indicate likely candidates for the assays described above, e.g., the cell survival or cholinergic activity assay; disclosed herein is an IGF-I-receptor displacement assay designed for such a purpose. Methods for measuring the ability of NGF or its functional derivatives to bind its receptors are known to those skilled in the art. Those polypeptides which appear to promote cell survival or cholinergic activity under one or more of the above assays may be further tested, by appropriate in vivo administration, for their ability to counteract the degenerative effects of aging, injury or disease in the nervous system or other tissue of an animal.

The use of any polypeptide as a therapeutic raises the issue of stability of the polypeptide after administration to the organism, when it is exposed to the action of various peptidases both within and without the target tissue. Where lack of such stability is expected to be a problem, certain stability-enhancing modifications disclosed herein may be made to the polypeptide. Other modifications designed to facilitate transport of the polypeptide across the blood-brain barrier may be made to the polypeptide, as disclosed herein.

- 12 -

The method of the invention is useful for therapeutically treating a disorder of a human or other mammal characterized by the death of cells, particularly neural cells, including disorders attributable to a disease or aging of, or injury to, such neuronal cells. The neurotrophic peptides, including the IGFs and/or their functional derivatives, and combinations of IGFs and/or their functional derivatives with NGF or its functional derivatives are useful for the treatment of neurodegenerative diseases such as Alzheimer's disease, stroke, epilepsy, amyotrophic lateral sclerosis and Parkinson's disease, as well as general age-related neuronal loss, conditions which have proven particularly intractable to treatment by alternative methods.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The drawings are first described.

Drawings

Fig. 1 is a graph illustrating the effect of IGF-I on the survival of cholinergic neurons in rat spinal cord cultures.

Fig. 2 is a graph showing the effect of IGF-II and IGF-III on the survival of cholinergic neurons in rat spinal cord cultures.

Fig. 3 is a graph illustrating the effect of certain synthetic peptide fragments of IGF-I and IGF-II on the survival of cholinergic neurons in rat spinal cord cultures.

Fig. 4 is a graph depicting the effect on brain ornithine decarboxylase activity of increasing doses of IGF-I injected into the brains of immature rats.

Fig. 5 is a graph showing the effect on brain ornithine decarboxylase activity of injection of IGF-I or synthetic peptide fragments of IGFs into the brains of immature rats.

- 13 -

Fig. 6 is a graph depicting the effect on brain ornithine decarboxylase activity of injection of IGF-I into the brains of mature rats.

5 Fig. 7 is a graph illustrating the effect of an IGF-II derivative and of IGF-I on survival of cortical cells, as assessed by leucine incorporation.

Fig. 8 is a graph illustrating the effect of an IGF-II derivative and IGF-I on the survival of cortical neurons, as assessed by morphological characteristics.

10 Fig. 9 is a graph illustrating the additive effect of NGF (at saturating concentration) and IGF-I on ChAT activity in cultured rat septal cells.

Fig. 10 is a graph illustrating the additive effect of NCF and IGF (at saturating concentration) on ChAT activity in
15 cultured rat septal cells.

Fig. 11 is a graph illustrating the effect of timed addition of NGF and IGF-I on ChAT activity in cultured septal cells.

Fig. 12 is a graph illustrating the effect of NGF and
20 IGF-I on the number of AChE positive cells in septal cultures.
The Peptides

The present invention is directed, inter alia, to the modification of neuroactive polypeptides such as IGF-I and IGF-II and their functional derivatives, and their use, both
25 with and without accompanying administration of NGF or functional derivatives of NGF, as therapeutics for certain neurological diseases or disturbances characterized by increased vulnerability of neurons to dying. A "neuroactive polypeptide" or "growth factor" is defined as a polypeptide
30 which exerts a survival enhancing effect on neuronal cells: e.g., the IGFs, e.g., IGF-I and IGF-II, Nerve Growth Factor (NGF), Epidermal Growth Factor, Fibroblast Growth Factor, and insulin. A "functional derivative" of a polypeptide is a compound which is a fragment, an analog, or an analog of a

- 14 -

fragment of that molecule and which possesses the desired biological activity, herein defined as the ability to promote survival and/or cholinergic activity of neuronal cells. A "fragment" of a polypeptide refers to any polypeptide subset of that polypeptide. An "analog" of a polypeptide refers to a molecule having biological activity but possessing some structural differences compared to the polypeptide: e.g., an altered amino acid sequence, or the presence of additional chemical moieties not normally a part of the molecule. Such moieties (introduced, for example, by acylation, alkylation, cationization, or glycosylation reactions) may improve the molecule's solubility, absorption, transport, biological half-life, etc. Alternatively, or in addition, some moieties may decrease the toxicity of the molecule, or eliminate or attenuate any undesirable side effect of the molecule.

Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980). Although some derivatives of IGF-I, IGF-II, and NGF may be inoperative alone or in combination, a person skilled in the art disclosed herein can recognize which are operative and which are not, as will be explained in more detail below. A "transmitter enhancer" is a polypeptide which causes an increase in the level of a transmitter. NGF is an example of a transmitter enhancer. A "transmitter" is a neurotransmitter, e.g., acetyl choline. A "transmitter-specific enzyme" is an enzyme present in neurons and involved in transmitter metabolism, e.g., in the case of cholinergic neurons, acetyl choline esterase (AChE) or choline acetyl transferase (ChAT). A "neuronal cell" is a neuron.

Some of the compounds within the scope of this invention are depicted in Table 1, which shows the amino acid sequences (expressed using single-letter abbreviations as defined in Table 2) of IGF-I, IGF-II, and a number of functional derivatives of IGF-I and IGF-II. These derivatives

- 15 -

were selected for study on the basis of one or more of the following criteria, which are related to the ability to bind to IGF-I or IGF-II receptors, and thus are useful for identifying additional functional derivatives of the invention: (1) conservation of amino acid sequence among species; (2) presence of "conservative" amino acid substitutions among species (i.e., amino acids with similar shape, charge or other salient characteristics); (3) receptor shielding of tyrosine residues from radioiodination (Maly and Luthi, J. Biol. Chem. 263:7068-7072 (1988)); (4) predominance of hydrophilic residues, suggesting the location of a receptor-binding domain on the surface of the polypeptide, a presumptive requirement for receptor interaction; and (5) consideration of hydrophobic and polar regions of three-dimensional models (e.g., Blundell et al., Fed. Proc. 42:2592-2597 (1983)) and identifying therefrom regions which are possible binding sites. Analogous factors can be applied in the design of NGF functional derivatives.

Since the ability of peptides to penetrate the blood-brain barrier is related to their lipophilicity or their net ionic charge, suitable modifications of these peptides (e.g., by substituting pentafluorophenylalanine for phenylalanine, or by conjugation to cationized albumin) to increase their transportability (Kastin et al, Pharmac. Biochem. Behav. 11:713-716 (1979); Rapoport et al., Science 207:84-86 (1980); Pardridge et al., Biochem. Biophys. Res. Commun. 146:307-313 (1987); Riekkinen et al., Peptides 8:261-265 (1987)) may be important for their bioavailability following administration outside the blood-brain barrier, and these modifications are within the scope of the invention. In addition, since bioavailability of peptides may be limited by their susceptibility to degradation by proteases and peptidases (Littlewood et al., Neurochem. Int. 12:383-389 (1988)), modifications of these peptides (e.g., replacement of

- 16 -

L-amino acids with D-amino acids) to increase their metabolic stability (Coy et al., 1976) may also be important for their therapeutic efficacy, and these modified peptides are also within the scope of the invention.

5 Functional derivatives of the invention include, among others, peptides which vary from the native IGF or NGF molecules in any one or more of the following ways:

1. Chemical modification of the amino and carboxyl groups present at the respective ends of the peptides.

10 2. Replacement of one or more of the amino acid residues in the native sequence with biologically compatible other amino acid residues.

15 3. Replacement of one or more of the amino acid residues in the native sequence with chemically modified, biologically compatible other amino acid residues.

4. Deletion of one or more of the amino acid residues in the native sequence.

20 5. Repetition of one or preferably a sequence of several amino acid residues in the native sequence, with or without chemical modification to, or replacement or deletion of, one or more of the members of the sequence.

6. Cyclization, that is, joining the amino and carboxyl ends of the linear peptide.

25 7. Linkage of a IGF-I, IGF-II, NGF, or a functional derivatives of any of IGF-I, IGF-II, or NGF with another molecule such as a polypeptide (e.g., another fragment of IGF-I, IGF-II, or NGF) or a carbohydrate, by means of a disulfide, peptide, ester or other covalent bond.

30 The invention also utilizes as a preferred subgroup within the IGF functional derivatives described above, those functional derivatives having the sequence:

$R_1-AA_1-AA_2-AA_3-AA_4\ldots AA_n-R_2$, wherein $AA_1, AA_2, AA_3, AA_4\ldots AA_n$ are amino acid residues of IGF or of the IGF-peptide subsets or are conservative replacements for them

- 17 -

as defined in Table 2, and n is any integer from 5 to 70 for IGF-I functional derivatives and 5-67 for IGF-II functional derivatives. R_1 is attached to the amino group of AA_1 and selected from the group of hydrogen, lower (C_{1-6}) alkyl, lower alkyl carbonyl, lower alkenyl, lower alkynyl, formyl, lower (C_{6-10}) aryl, aroyl, aryloxy-carbonyl, aralkyloxy-carbonyl, lower alkyloxycarbonyl, benzoyl, 1- or 2-thenoyl, nicotinoyl, dihydronicotinoyl, N-alkyldihydronicotinoyl, isonicotinoyl, and

N-alkyldihydroisonicotinoyl. The carboxyl-terminal substituent (R_2) of the peptides is selected from the following: OH; NH_2 ; OR_3 , wherein R_3 is a lower alkyl or a lower aryl; OR_3OH , wherein R_3 is defined as above; and $NH-R_3$ or $N(CH_3)R_3$, wherein R_3 is defined as above. Alternatively, the carboxyl group of the carboxyl-terminal amino acid may be replaced by any one of $-PO_3H_2$, $-B(OH)_2$, $-CH_2OH$, $-SO_3H$ or a 5-tetrazole group.

The invention also utilizes as a preferred subgroup within the NGF functional derivatives described above, those functional derivatives having the sequence:

$R_1-AA_1-AA_2-AA_3-AA_4 \dots AA_n-R_2$, wherein $AA_1, AA_2, AA_3, AA_4 \dots AA_n$ are amino acid residues of NGF or its functional derivatives or are conservative replacements for them as defined in Table 2, and n is an integer corresponding to the number of amino acid residues in NGF or in a functional derivative thereof. R_1 is attached to the amino group of AA_1 and selected from the group of hydrogen, lower (C_{1-6}) alkyl, lower alkyl carbonyl, lower alkenyl, lower alkynyl, formyl, lower (C_{6-10}) aryl, aroyl, aryloxy-carbonyl, aralkyloxy-carbonyl, lower alkyloxycarbonyl, benzoyl, 1- or 2-thenoyl, nicotinoyl, dihydronicotinoyl, N-alkyldihydronicotinoyl, isonicotinoyl, and N-alkyldihydroisonicotinoyl. The carboxyl-terminal substituent (R_2) of the peptides is selected from the following: OH;

- 18 -

NH₂; OR₃, wherein R₃ is a lower alkyl or a lower aryl;
OR₃OH, wherein R₃ is defined as above; and NH-R₃ or
N(CH₃)R₃, wherein R₃ is defined as above. Alternatively,
the carboxyl group of the carboxyl-terminal amino acid may be
5 replaced by any one of -PO₃H₂, -B(OH)₂, -CH₂OH, -SO₃H
or a 5-tetrazole group.

The amino-terminal amino group and/or the lysine,
serine or threonine side chains occurring within the peptide
may optionally be acylated by formyl, acetyl, propionyl, and
10 similar lower alkylacyl residues or by aryl or heterocyclic
acyl residues such as benzoyl, thenoyl, nicotinoyl,
isonicotinoyl, n-alkylnicotinoyl and their dihydro and
tetrahydro derivatives. Such modifications would be expected
to enhance the blood-brain barrier permeability of the
15 therapeutic agent (Creveling et al., *Experientia* 25:26-27
(1969); Bodor et al., *Science* 214:1370-1372 (1981)).

In peptide sequences containing proline, glutamic
acid, or aspartic acid at the amino-terminus, the amino
terminal amino acid may optionally be replaced by
20 L-pyroglutamic acid.

The fragment polypeptides of IGF-I, IGF-II, and NGF
are subsets of the IGF-I, IGF-2, and NGF molecules
(respectively) containing fewer amino acid residues than the
native molecules. Preferred IGF sequences are of 5-40 residues
25 and most preferred are sequences of 6-25 residues. A portion
of the amino acids of the fragments may be substituted with
conservative replacements or deletions which improve the
chemical or biological stability of the product peptides or
improve their transport across the blood-brain barrier.
30 Preferably, no more than 30% and more preferably no more than
20%, of the amino acid residues are replaced or deleted. A
listing of suitable conservative replacements is given in Table
2, along with a key to the single-letter abbreviations for the
common, naturally-occurring amino acid residues found in

- 19 -

proteins. Certain other abbreviations used in Table 2 are herein defined: by Nle is meant norleucine, by Aib is meant aminoisobutyric acid, by AdaA is meant β -adamantylalanine, by AdaG is meant α -adamantylglycine, by homo-Arg is meant L-homoarginine, by D-homo-Arg is meant D-homoarginine, by Acp is meant ϵ -aminocaproic acid, by Chg is meant L- α -cyclohexylglycine, and by allo-Thr is meant L-allothreonine. Additionally, by Cha is meant β -cyclohexyl-alanine, by Me is meant methyl (CH_3), by Orn is meant ornithine, by pyro-Glu is meant the pyroglutamyl group, by Met(O) and D-Met(O) are meant the sulfoxides derived from L- and D-methionine, respectively, by β -Ala is meant β -alanine, by Acn is meant acetamidomethyl, by L-Dopa is meant 3-(3,4-dihydroxyphenyl)-L-alanine, and by Bpa is meant 4-benzoyl-phenylalanine.

The symbolism and abbreviations used are otherwise those recommended by the IUPAC-IUB Joint Commission on Biochemical Nomenclature, "Nomenclature and Symbolism for Amino Acids and Peptides, Recommendations 1983" J. Biol. Chem. 260:14-42 (1985). As is conventional, these same symbols are used to define the corresponding residues of the amino acids when they are linked into a peptide chain. Where the amino acid residue has isomeric forms, it is the L-form of the amino acid that is represented unless otherwise expressly indicated. In accordance with conventional representation, the amino group at the N-terminus of each peptide appears to the left and the carboxyl group at the C-terminus to the right.

Besides the amino acid substitutions suggested above, other methods of improving transport of the polypeptide across the blood-brain barrier, such as chemical modification of the polypeptide, may be employed. In any chemical modification procedure, the polypeptide may first be attached to its receptor in order to protect and maintain the receptor-binding site structure during the chemical modification process, which

- 20 -

can comprise, for example, cationization (according to the method, for example, of Pardridge et al., 1987) or glycosylation (according to the method of Schwartz et al., Arch. Biochem. Biophys. 181:542-549 (1977)).

5 Uses of the Peptides

As described more fully below, the present invention provides novel uses of IGF-I and IGF-II and their functional derivatives, and of IGF-I, IGF-II, and their functional derivatives in combination with NGF and its functional derivatives, as agents for the treatment of diseases or disturbances characterized by an increased risk of cell death, including in particular, neuronal cell death. The bioactivity of each polypeptide (or combination of polypeptides) of the invention may be conveniently assayed by a brain ornithine decarboxylase assay, a spinal cord choline acetyl transferase assay, a cultured septal cell assay, or a cultured cortical cell assay, all of which are described in detail below. Alternatively, the polypeptides may first be screened by a receptor-growth factor displacement assay, e.g., the receptor-IGF-I displacement assay described below, which measures the polypeptide's ability to displace labelled IGF-I bound to receptors in homogenized brain tissue. This assay has been demonstrated to correlate with the polypeptide's bioactivity as measured by the two enzymatic assays. As described in the examples below, these assays disclose previously unknown bioactivity of IGF-I, IGF-II, IGF-III and some functional derivatives of these molecules both alone, and in combination with NGF or functional derivatives of NGF. Thus, the peptides of this invention should be useful for administration to humans or other mammals who suffer from neurological diseases or disturbances characterized by increased risk of neuronal cell death, as described above. These neurological diseases or disturbances include but are not limited to: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, and concussive or penetrating injuries of the brain or spinal cord.

10
15
20
25
30
35

- 21 -

The formulations of this invention are useful for parenteral administration, for example, intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular, intraspinal, intracisternal, intraperitoneal, topical, intranasal, aerosol, scarification, and also for oral, buccal, rectal or vaginal administration. The compositions can be formulated for parenteral administration to humans or other mammals in therapeutically effective amounts (e.g., amounts which eliminate or reduce the patient's pathological condition) to provide therapy for the neurological diseases described above.

The compounds provided herein can be formulated into pharmaceutical compositions by admixture with pharmaceutically acceptable nontoxic excipients and carriers. As noted above, such compositions may be prepared for use as parenteral administration, particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols.

The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences. Formulations for parenteral administration may contain as common excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the peptides. Other potentially useful parenteral delivery systems for these peptides include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration contain as

- 22 -

excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or citric acid for vaginal administration.

The materials of this invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients, e.g., other growth factors which could facilitate neuronal survival in neurological diseases, or peptidase or protease inhibitors.

The concentration of the compounds described herein in a therapeutic composition will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g., hydrophobicity) of the compounds employed, and the route of administration. In general terms, the compounds of this invention may be provided in an aqueous physiological buffer solution containing about 0.1 to 10% w/v compound for parenteral administration. Typical dose ranges are from about 1 µg/kg to about 1 g/kg of body weight per day; a preferred dose range is from about 0.01 mg/kg to 100 mg/kg of body weight per day. The preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the neurological disease, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the compound excipients, and its route of administration.

The present invention will be further illustrated by the following examples. These examples are not to be construed as limiting the scope of the invention, which is to be determined solely by the appended claims.

- 23 -

EXAMPLE 1

Recombinant human IGF-I, IGF-II, and IGF-III, as well as several chemically synthesized peptides consisting of partial sequences of IGF-I or IGF-II, were obtained from commercial sources as indicated in Table 1. ¹²⁵I-labeled [Threonine⁵⁹]IGF-I was obtained from Amersham (Arlington Heights, IL). Other peptides consisting of partial sequences of IGF-I or IGF-II were chemically synthesized using Fmoc chemistry on a Milligen Biosearch Model 9600 Peptide Synthesizer, and purified on Hewlett-Packard Models 1050 and 1090M HPLCs according to the method of Hudson, J. Org. Chem. 53:617-624 (1988). Fmoc amino acids, BOP (Castro's reagent), and resins were purchased from Biosearch (San Raphael, CA 94901) and Bachem Bioscience, Inc. (Philadelphia, PA 19104). Solvents were purchased from Burdick and Jackson (Muskegon, MI 49442). Other reagents were purchased from Sigma Chemical Co. (St. Louis, MO 63178).

Brain tissue containing the cerebral cortex and cerebellum was dissected from adult Sprague-Dawley rats (Hilltop Lab Animals, Inc. Scottsdale, PA) and homogenized at low power for 5 minutes in a Brinkmann Polytron homogenizer (Westbury, NY) containing 50 volumes of ice-cold buffer consisting of 10 mM HEPES, 0.5% BSA, 0.0125% NEM, 0.025% bacitracin, and 100 KIU/ml aprotinin, pH 7.6 (Bohannon et al., Endocrinology 119:943-945 (1986)). Following homogenization, the tissue was collected after centrifugation at 7800 x g for 20 minutes and resuspended in 10 volumes of assay buffer. Tissue (50 µl), 100 µl ¹²⁵I-[Threonine⁵⁹]IGF-I (20 pM), and 50 µl of buffer or peptides of varying concentration were added to 96-well plates and incubated on ice for 3 hours. After the incubation period, the tissue was collected on Whatman GF/C filters that had been pre-soaked in 0.01% polyethyl nimine and washed four times with ice-cold assay buffer using a Brandel cell harvester (Gaithersburg, MD). The filters were removed and the bound ¹²⁵I-[Threonine⁵⁹]IGF-I was measured using a Beckman Model 5500B Gamma Counter.

- 24 -

Table 3 summarizes the results of the ^{125}I -[Threonine⁵⁹]IGF-I displacement assay utilizing native IGFs and IGF fragments. The results demonstrate that, while IGF-I and IGF-III are potent displacers of ^{125}I -[Threonine⁵⁹]IGF-I, IGF-II is essentially inactive, indicating that the assay is selective for the identification of IGF-I-like molecules. In this assay, IGF-I(24-41) alone or in combination with IGF-II(54-67) were active in displacing ^{125}I -[Threonine⁵⁹]IGF-I. IGF-II(54-67) alone, and several other fragments listed in Table 3 were not significantly effective displacers of ^{125}I -[Threonine⁵⁹]IGF-I.

- 25 -

EXAMPLE 2

Brains were removed intact from adult Sprague-Dawley rats, frozen on powdered dry ice, and cut into 20µm sections (at the level of the cerebellum and brain stem) which were thaw-mounted onto gelatin-coated glass microscope slides (Herkenham and Pert, J. Neurosci. 2:1129-1149 (1982)). Using a modification of the method of Bohannon et al. (1986), the tissue sections were covered with 250 µl of HEPES assay buffer (see Example 1) containing 0.01 nM ^{125}I -[Threonine⁵⁹]IGF-I alone or in combination with unlabeled IGF-I, IGF-II, or synthetic peptide fragments thereof. The sections were incubated at 4°C for 24 hours and then rinsed in three 1-minute changes (200 ml each) of ice-cold HEPES assay buffer. The tissue sections were then wiped off the slides with filter paper, and the tissue-bound radioactivity was measured in a Beckman Model 5500B Gamma Counter.

In this assay, in contrast to the assay described in Example 1, ^{125}I -[Threonine⁵⁹]IGF-I binding was potentially displaced by both IGF-I and IGF-II, indicating the utility of this assay for detecting potentially active derivatives of both of these molecules (Table 4). ^{125}I -[Threonine⁵⁹]IGF-I binding was displaced by IGF-II(33-40), but not by IGF-II(54-67).

EXAMPLE 3

The activity of IGF-I, IGF-II, or synthetic peptide derivatives of these molecules was assayed on dissociated cultures of 14-day embryonic rat spinal cord neurons. The spinal cord neurons were obtained from trypsin-dissociated spinal cords, plated, incubated with peptides, and subsequently (48 hr later) assayed for choline acetyltransferase activity as described by McManaman et al., Dev. Biol. 125:311-320 (1988).

- 26 -

In this assay, IGF-I was found to produce a substantial, dose-dependent increase in choline acetyltransferase activity (Fig. 1), suggesting that IGF-I can dramatically enhance the cholinergic activity of spinal cord cholinergic neurons. Furthermore, IGF-II and IGF-III were found to be active in the spinal cord assay (Fig. 2). In addition, IGF-I(24-41) and IGF-II(33-40) were also found to produce a dose-dependent increase in choline acetyltransferase activity, indicating that each peptide is an active IGF functional derivative (Fig. 3).

EXAMPLE 4

The in vivo activity of IGF-I, IGF-II or synthetic peptide derivatives of these molecules was tested using a biochemical marker for CNS neurotrophic activity, the induction of brain ornithine decarboxylase. The induction (i.e. increased activity) of ornithine decarboxylase has been reported to be a general marker for the actions of a variety of trophic factors. (Schwartz et al., Dev. Brain Res. 1:403-413 (1981); Kanje et al., Brain Res. 381:24-28 (1986); Russell et al., Life Sci. 19:1297-1306 (1976); MacDonnell et al. Proc. Natl. Acad. Sci. USA 74, 4681-4684 (1977); Rinehart et al. Proc. Natl. Acad. Sci. USA 82, 4365-4368 (1985)).

Sprague-Dawley rats, 4 days old, were injected intracerebrally (in the area of the lateral ventricle) with 5 µl of 0.1 M phosphate-buffered saline (PBS) containing IGF-I, IGF-II or a synthetic peptide derivative (1.25-2.5 µg dose, with 6 animals per treatment group). After 6 hours, the brains were removed, and ornithine decarboxylase was assayed essentially as described by Lewis et al., Proc. Natl. Acad. Sci. USA 75:1021-1023 (1978).

Administration of IGF-I produced a dose-dependent increase in brain ornithine decarboxylase activity (Fig. 4). In addition, both IGF-I(24-41) and IGF-II(54-67) increased brain ornithine decarboxylase activity (Fig. 5; these peptides are referred to in Fig. 5 as IGF-I (2-4) and IGF-I(5-6), respectively).

- 27 -

EXAMPLE 5

To determine whether the induction of brain ornithine decarboxylase by IGF-I was limited to developing animals, IGF-I was also injected intraventricularly into the lateral ventricles of adult Sprague-Dawley rats. After 6 hours, the brains were removed, dissected into several regions (cerebral cortex, medial septum, and hippocampus), and then assayed for ornithine decarboxylase activity as described in Example 4. As shown in Fig. 6, IGF-I stimulated ornithine decarboxylase activity in all brain regions assayed. This result indicates that IGF-related molecules have potential utility in widespread regions of the brain.

EXAMPLE 6

The ability of IGF-I and a synthetic derivative of IGF-II (IGF-II(54-67)) to increase the incorporation of [³H]-leucine and to promote the survival of neurite bearing cells was examined in cultured rat cortical cells (the numbers "54-67" in IGF-II indicate the fragment includes amino acid residues 54-67 of native IGF-II). IGF-II(54-67), like IGF-I, increased [³H]-leucine incorporation in low density 24 hour mixed cortical cultures, as shown in Fig. 7. IGF-II(54-67) also displayed IGF-I-like survival-promoting activity in that it increased the survival of cortical neurons (as determined by the presence of neurite bearing cells), as shown in Fig. 8.

Measurements were performed, using standard techniques known to those skilled in the art, on dissociated cortical cells obtained from day 18-19 embryonic rats. Cells were seeded at $1.5 \times 10^4/\text{cm}^2$ on poly-l-ornithine-laminin coated plastic tissue culture cells in serum-free N2 medium (Bottenstein et al. Proc. Natl. Acad. Sci. U.S.A. 76: 514-517 (1978)). [³H]-leucine was added to cells at plating for the incorporation assay. Cultures were terminated 24 hours after plating and measured for either [³H]-leucine incorporation or for the number of neuritic cells by microscopic examination.

- 28 -

EXAMPLE 7

The effect of simultaneous administration of IGF-I and NGF on ChAT activity was assayed in cultured septal neurons. ChAT is the initial enzyme in the synthesis of the neurotransmitter, acetylcholine, and is a specific biochemical marker for cholinergic neurons. Assay of this enzyme may be used as an indication of the effects of IGF (and other factors) on the survival of cholinergic neurons and/or regulation of this enzyme. An additive increase in ChAT activity was seen with saturating concentrations of NGF combined with saturating or sub-maximal concentrations of IGF-I, as shown in Fig. 9. In Fig. 9 open squares represent IGF-I, diamonds indicate IGF-I + 2nM NGF, open circles indicate 2nM NGF, and the horizontal line at 403 DPM represents uninduced cells. A similar additive effect was seen when saturating concentrations of IGF-I were combined with saturating or sub-maximal concentrations of NGF, as shown in Fig. 10. In Fig. 10 open squares indicate NGF, diamonds indicate NGF + 25nM IGF-I, open circles represent 25nM IGF-I, and the horizontal line at 554 DPM represents uninduced cells. The percent increases in ChAT activity over control uninduced cells are summarized in Table 5.

Cultured rat septal cell experiments were performed generally as described in Hartikku and Hefti, J. Neuroscience, 8:2967-2985 (1985), Hayashi and Patel, Dev. Brain Res., 36:109-120 (1987), and as follows. Dissociated cell cultures of the septal region of day 17 embryonic rats were prepared by standard techniques known to those skilled in the art, using enzymatic (Dispase, Collaborative Research) dissociation of tissue. Cells were seeded (plated) at 6×10^5 cells/cm² in poly-L-ornithine-laminin coated plastic tissue culture wells, and cultured in serum-free N2 medium (Bottenstein et al., 1978) for 5 days without feeding. Control (uninduced) cultures received no added growth factors; induced cultures received the concentrations of IGF-I and NGF indicated in Figs. 9 and 10 at

- 29 -

the time of plating. NGF is commercially available. ChAT was assayed by the method described in McManaman, et al. Dev. Biol. 125:311-320 (1988). AChE staining was performed according to the method of Hartikka and Hefti, J. Neuroscience 8:2967-2985 (1988).

Positive cytochemical staining for the enzyme acetylcholinesterase (AChE) has been shown to be a reliable marker for choline acetyltransferase positive neurons in rat septal cell cultures (Hartikka and Hefti, J. Neuroscience 8:2967-2985 (1988)).

EXAMPLE 8

The sequence in which NGF and IGF-I are added to the culture medium has a significant effect on the magnitude of the increase of ChAT activity in cultured rat septal cells, as shown in Fig. 11. In Fig. 11 A represents 2nM IGF, B represents 25nM IGF-I, C represents IGF-I + NGF, both added 5 days before assay, and D IGF-I added at the beginning of the experiment + NGF added on day 3 of the experiment, with assay on day 5 of the experiment. When added separately, NGF or IGF-I increased ChAT activity 50 to 60% in a 5 day old culture. When NGF and IGF-I were present together for the entire 5 days the NGF and IGF-I effects on ChAT activity were additive (a 100% increase), as shown in Figs. 9, 10, and 11.

When IGF-I was present from the beginning of the experiment and NGF was added on day 3, the ChAT activity on day 5 was increased by 300% over uninduced cultures, as shown in Fig. 11. Thus it has been discovered that IGF-I and NGF act in a previously unknown, complimentary manner to enhance the survival and neurotransmitter-synthesizing capacity of cholinergic neurons.

Cultured rat septal cell experiments were performed as described above.

- 30 -

EXAMPLE 9

We have shown that under specific culture conditions (4×10^5 cells/cm² in the presence of medium containing 10% bovine calf serum), IGF-I increased the number of AChE positive cells by 3-4 fold over control, growth factor-free cultures, Fig. 12. In Fig. 12 A represents uninduced cells, B represents cells treated with 2nM NGF, C represents cells treated with 100nM IGF-I, and D represents cells treated with NGF + IGF-I. (DPM= disintegrations per minute.) NGF under the same conditions, did not affect the number of AChE positive cells. These results indicate that IGF-I has a greater effect on cholinergic cell survival (i.e. increases cholinergic survival), while NGF regulates (increases) ChAT activity in existing cholinergic neurons.

EXAMPLE 10

Cationization is a process by which free carboxyl groups of acidic amino acid residues on a polypeptide (i.e., aspartic acid and glutamic acid residues) are modified in order to increase the net positive charge on the polypeptide. The process of cationization has been used to enhance the cellular uptake of large molecules such as albumin and horseradish peroxidase into mouse fibroblast cells (Shen et al., Proc. Nat. Acad. Sci. USA 75:1872-1876 (1978)). Kumagai et al., J. Biol. Chem. 262:15214-15219 (1987), using intact microvessels from bovine brain that are reportedly a model system for measuring transport across the blood-brain barrier, showed that uptake of cationized albumin by isolated bovine brain microvessels was enhanced when compared with uptake of native albumin.

For global modification of free carboxyl groups, the polypeptide (e.g., NGF, IGF-I, IGF-II or a functional derivative) would be reacted with excess hexamethylenediamine (HMD) (15.5 g/g total protein) for 30 minutes at room temperature, followed by covalent coupling of HMD with 1-ethyl-3[-3-dimethyl-aminopropyl] carbodiimide hydrochloride

- 31 -

(EDAC) (1.0g/g total protein) for 3 hours at room temperature. Unreacted species may be removed by filtration using Centricon-3 MPS-1 separation devices (Amicon, Danvers, MA) or ion exchange chromatography. The purified polypeptide may be analyzed using isoelectric focusing to determine the amount of cationization.

If the global modification is used on a polypeptide that is a ligand which binds to a cell surface receptor, and the modification produces a molecule lacking biological activity, the cationization process may be repeated as described above except that the polypeptide would be pre-bound to an appropriate receptor prior to cationization, in order to protect the receptor-binding site on the polypeptide. This protection procedure would be carried out as follows: Tissue, e.g., brain, containing receptors for the polypeptide of interest (e.g., IGF-I) is prepared as described above in Example 1. After incubation with the polypeptide ligand for 2 hours @ 4°C to permit receptor binding, the reaction mixture is brought to room temperature, and the cationization procedure carried out using HMD and EDAC as described above. The reaction mixture is then centrifuged at 16,000 rpm at 4°C for 30 sec in an SS-34 rotor in a Sorvall RC5B centrifuge. The supernatant is discarded and the pellet washed three times in PBS with bovine serum albumin (1 mg/ml). The pellet is resuspended in 100mM acetic acid and incubated for 10 min @ 4°C to release the cationized polypeptide from its receptors. After centrifugation again at 16,000 rpm, the supernatant, which contains the released cationized polypeptide, is pH-neutralized with NaOH. It may then be analyzed by isoelectric focusing, by a receptor-binding assay as described in Example 1, or by any appropriate assay for biological activity.

- 32 -

EXAMPLE 11

An alternative to the global modification method is to couple polylysine to at least one free carboxyl group on polypeptide (such as IGF-I, IGF-II, or a functional derivative of either) with or without receptor protection as described above in Example 10. The procedure follows the method of Shen et al., 1978. For example, polylysine, IGF-I and carbodiimide are added in a 1:1:1 ratio in water or buffer for 3 hours at room temperature. The modified protein would be separated and analyzed as described above in Example 10.

EXAMPLE 12

A third method for modifying protein carboxyl groups to enhance blood brain barrier transport is to form esters with diazomethane or N,N-dimethylformamide R acetals (DMF acetals), where R is dimethyl, diethyl, dibutyl, dibenzyl, etc. This type of modification rapidly forms esters from negatively charged carboxylic acid groups, thus increasing the overall positive charge. An additional benefit from this modification is that these added ester groups may be such that they increase the overall lipophilicity of the polypeptide and may be removed by intrinsic esterases in vivo to yield intact growth factor. The procedure for this modification, with or without receptor protection as described above in Example 10, is to react diazomethane or DMF acetals with the polypeptide in a 1:1 ratio in solution for 30 min. at room temperature, followed by purification and characterization as described above in Example 10.

EXAMPLE 13

A fourth method of cationization, with or without receptor protection as described above in Example 10, combines the advantages of polylysine cationization with the formation of cleavable esters to enhance blood-brain barrier transport, as well as to yield intact growth factor following transport. Polylysine may be made reactive by reaction with

- 33 -

benzyloxylacetyl chloride followed by hydrogenation and mild esterification procedures (Hassner et al., Tet. Let. 46:4475-4478 (1978); Mihara et al., Int. J. Peptide Protein Res. 28:141-145 (1986)). Alternatively, DMF acetal derivatives capable of reacting with polylysine could be used to link polylysine to free carboxyl groups using ester linkages.

EXAMPLE 14

A further type of polypeptide modification is glycosylation: the introduction of glucose or similar residues by reductive amination using, for example, glucose and sodium cyanoborohydride (NaCNBH_3). Glycosylation of proteins has been shown to enhance the cellular uptake of these proteins and may prove useful for improving blood-brain barrier transport (Smith et al., Pharm. Res., in press). The procedure for glycosylation, with or without receptor protection as described above in Example 10, is based on the method of Schwartz et al., 1977, wherein a polypeptide such as IGF-I, IGF-II, or a functional derivative of either is combined with glucose and NaCNBH_3 in a molar ratio of 1:300:1600 in 200 mM phosphate buffer at pH 7 for at least 24 hr at 37 C°. Unreacted entities may be removed as described in Example 10, or with lectin affinity chromatography. In previous studies using glycosylated albumin, the modified albumin was taken up by rat epididymal microvessels at a greater rate than was native albumin (Williams et al., Proc. Nat. Acad. Sci. USA 78:2393-2397 (1981)).

EXAMPLE 15

Blood-Brain Barrier Transport Model: Method of Audus et al., Ann.N.Y.Acad.Sci. 507:9-18 (1987).

Microvessel endothelial cells are isolated from the cerebral gray matter of fresh bovine brains. Brains are obtained from a local slaughter house and transported to the laboratory in ice cold minimum essential medium (MEM) with

- 34 -

antibiotics. Under sterile conditions the large surface blood vessels and meninges are removed. The cortical gray matter is removed by aspiration, then minced into < 1 mm cubes. The minced gray matter is then incubated with 0.5% dispase (BMB, Indianapolis, IN) for 3 hours at 37°C in a shaking water bath. Following the 3 hour digestion, the mixture is concentrated by centrifugation (1000 xg for 10 min.), then resuspended in 13% dextran and centrifuged for 10 min. at 5800 xg. Supernatant fat, cell debris and myelin are discarded and the crude microvessel pellet is resuspended in 1mg/ml collagenase/dispase and incubated in a shaking water bath for 5 hours at 37°C. After the 5-hour digestion, the microvessel suspension is applied to a pre-established 50% Percoll gradient and centrifuged for 10 min at 1000 xg. The band containing purified endothelial cells (second band from the top of the gradient) is removed and washed two times with culture medium (50% MEM/50% F-12 nutrient mix). The cells are frozen (-80°C) in medium containing 20% DMSO and 10% horse serum for later use.

After isolation, approximately 5×10^5 cells/cm² are plated on culture dishes or 5-12 µm pore size polycarbonate filters that are coated with rat collagen and fibronectin. 10-12 days after seeding the cells, cell monolayers are inspected for confluency by microscopy.

Characterization of the morphological, histochemical and biochemical properties of these cells has shown that these cells possess many of the salient features of the blood-brain barrier. These features include: tight intercellular junctions, lack of membrane fenestrations, low levels of pinocytotic activity, and the presence of gamma-glutamyl transpeptidase, alkaline phosphatase, and Factor VIII antigen activities.

The cultured cells can be used in a wide variety of experiments where a model for polarized binding or transport is required. By plating the cells in multi-well plates, receptor and non-receptor binding of both large and small molecules can

- 35 -

be conducted. In order to conduct transendothelial cell flux measurements, the cells are grown on porous polycarbonate membrane filters (Nucleopore, Pleasanton, CA). Large pore size filters (5-12 μm) are used to avoid the possibility of the filter's becoming the rate-limiting barrier to molecular flux. The use of these large-pore filters does not permit cell growth under the filter and allows visual inspection of the cell monolayer.

Once the cells reach confluency, they are placed in a side-by-side diffusion cell apparatus (Crown Glass, Sommerville, NJ). For flux measurements, the donor chamber of the diffusion cell is pulsed with a test substance, then at various times following the pulse, an aliquot is removed from the receiver chamber for analysis. Radioactive or fluorescently-labelled substances permit reliable quantitation of molecular flux. Monolayer integrity is simultaneously measured by the addition of a non-transportable test substance such as sucrose or inulin and replicates of at least 4 determinations are measured in order to ensure statistical significance.

TABLE 1

IGF PEPTIDE SEQUENCES

Peptide Name	Sequence	Source	Cat. #
Human IGF-I (Somatomedin-C)	GPETL CCAEL VDALQ FVCGD RGFYF HKPTG YGSSS- -RRAPQ TGIWD EC CFR SCOLR RLEMY CAPLK PAKSA	AMGEN ¹	14010
Human IGF-I (Somatomedin-C)	GPETL CCAEL VDALQ FVCGD RGFYF HKPTG YGSSS- -RRAPQ TGIWD EC CFR SCOLR RLEMY CAPLK PAKSA	PENINSULA ²	9010 Lot 15578
IGF-I(4-70) (Human Brain IGF)	TLCCAEI VDALQ FVCGD RGFYF HKPTG YGSSS- -RRAPQ TGIWD EC CFR SCOLR RLEMY CAPLK PAKSA	KABIGEN ³ KABIGEN ³	Lot 88:101G Lot S:25
IGF-I(24-41)	YFNKP TGYGS SSRRR PQT	PENINSULA ²	7308 Lot 007942
	YFNKP TGYGS SSRRR PQT	BACHEM ⁴	PGRO 080 Lot F297
	YFNKP TGYGS SSRRR PQT	Synthetic ⁵	
IGF-I(30-41)	GYGSS SRRAP QT	PENINSULA ²	7306 Lot 003251
IGF-I(62-70)	APLKP AKSA	PENINSULA ²	7318 Lot 015726
IGF-I(24-32)	YFNKP TGYG	Synthetic ⁵	
IGF-I(24-41)-AMIDE	YFNKP TGYGS SSRRR PQT-NH ₂	Synthetic ⁶	
IGF-I(33-41)-AMIDE	SSSRR APQT-NH ₂	Synthetic ⁶	
48-Acm-IGF-I(42-57)- AMIDE	^{Acm} GIVDE CC FRS COLRR L-NH ₂	Synthetic ⁷	

Peptide Name	Sequence	Source	Cat.#
IGF-I(33-41)	SSRR APQT	Synthetic ⁵	
IGF-I(28-41)	PTGY SSSRR APQT	Synthetic ⁵	
IGF-I(27-36)	KPTGY GSSSR	Synthetic ⁵	
IGF-II(54-67)	ALLET YCATP AKSE	PENINSULA ² 8	7308 Lot 010718
IGF-II(62-67)	TPAKS E		
IGF-II(33-40)	SRVSR RSR	PENINSULA ²	7304 Lot 016905
IGF-II	AYRPS ETLCG GELVD TLQFV CGORG FYFSR PASRV		
Somatostatin-A	SRRSR GIVEE <u>CCFRS</u> COLAL LETYC ATPAK SE	COLLABORATIVE ⁹ COLLABORATIVE ⁹	LOT 89-0172 LOT 89-0401

- 1 Angen, Thousand Oaks, CA 91320
- 2 Peninsula Laboratories, Belmont, CA 94002
- 3 Kabigen AB, S-112 87, Stockholm, Sweden
- 4 Bachem, Inc., Torrance, CA 90505
- 5 Synthesized on a Biosearch Solid Phase Peptide Synthesizer Model 9600 using Fmoc-Amino Acids linked to p-Alkoxybenzyl Alcohol Resins supplied by Bachem Bioscience, Inc. Philadelphia, PA 19104.
- 6 Synthesized on a Biosearch Solid Phase Peptide Synthesizer Model 9600 using 4-(2', 4'-Dimethoxyphenyl)-Fmoc-aminomethyl)-phenoxy Resin (A04719) supplied by Novabiochem, AG Laufelfingen, Switzerland.
- 7 Synthesized on a Biosearch Solid Phase Peptide Synthesizer Model 9600 using the resin identified in footnote 6. AcM = Acetamidomethyl substituent on the cysteine side-chain sulfur atom.
- 8 This compound is incorrectly listed in the Peninsula Laboratories catalog as "Insulin-like Growth Factor I (57-70)".
- 9 Collaborative Research, Inc., Bedford, MA 01730

TABLE 2
CONSERVATIVE AMINO ACID REPLACEMENTS

<u>For Amino Acid</u>	<u>Code</u>	<u>Replace with</u>
Alanine	A	D-Ala, Gly, Aib, B-Ala, Acp, or delete
Arginine	R	D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn or delete
Asparagine	N	D-Asn, Asp, D-Asp, Glu, D-Gln, Gln, D-Gln or delete
Aspartic Acid	D	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln or delete
Cysteine	C	D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr, or delete
Glutamine	Q	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp or delete
Glutamic Acid	E	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln, or delete
Glycine	G	Ala, D-Ala, Pro, D-Pro, Aib, B-Ala, Acp or delete
Isoleucine	I	D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met, or delete
Leucine	L	D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met or delete
Lysine	K	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn or delete
Methionine	M	D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val or delete
Phenylalanine	F	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, Ada-A, AdaG, cis-3,4, or 5-phenylproline, Bpa, D-Bpa or delete
Proline	P	D-Pro, L-l-thiazolidine-4-carboxylic acid, D- or L-l-oxazolidine-4-carboxylic acid (Kauer, U.S. Patent 4,511,390). or delete
Serine	S	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O) or delete
Threonine	T	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val or delete.
Tyrosine	Y	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His or delete
Valine	V	D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met, AdaA, AdaG or delete

- 39 -

TABLE 3

IGF-I RECEPTOR COMPETITION ASSAY SUMMARY

PEPTIDE (CONC.)	PERCENT MAX. BOUND (SD)	
IGF-I (10 pM)	100	(1.1)
IGF-I (40 nM)	9.6	(0.7)
IGF-II (40 nM)	92.1	(0.7)
IGF-III (40 nM)	17.6	(2.6)
IGF-I(24-41) (100 μ M)	44	(7)
IGF-I(24-41) (50 μ M)	99	(6)
IGF-I(24-41) (50 μ M) + IGF-II(54-67)(50 μ M)	49	(11)
IGF-II(54-67)(100 μ M)	94	(6)
IGF-I(62-70) (100 μ M)	83	(20)
IGF-I(30-41) (100 μ M)	94	(1.4)
IGF-II(62-67) (100 μ M)	83	(21)
IGF-II(33-40) (1mM)	92	(1.8)

- 40 -

TABLE 4

PEPTIDE	PERCENT MAX. BOUND
IGF-I (4 pM)	91
IGF-I (400 pM)	30
IGF-II (200 nM)	50
IGF-II (400 nM)	23
IGF-II (33-40)(1 mM)	76
IGF-II (33-40)(.10 mM)	82
IGF-II (54-67)(.25 mM)	167
IGF-II (54-67) (.025 mM)	132

TABLE 5

ADDITIVE EFFECTS OF NGF AND IGF I ON CHAT ACTIVITY IN CULTURED RAT SEPTAL CELLS

Growth factor	Concentration nM	% Increase over control
NGF	2.0	44
IGF I	1.3	20
	12.5	50
	25.0	37
2 nM NGF + IGF I	1.3	58
	12.5	93
	25.0	100
IGF I		44
NGF	0.02	56
	0.2	36
	2.0	44
25 nM IGF I + NGF	0.02	75
	0.2	100
	2.0	94

- 42 -

Other embodiments are within the following claims.
What is claimed is:

- 43 -

CLAIMS

1 1. A method of enhancing the survival of neuronal
2 cells in a mammal, said cells being at risk of dying, said
3 method comprising administering to said mammal an effective
4 amount of at least one of the following substances:

5 IGF-I;

6 a functional derivative of IGF-I;

7 IGF-II; or

8 a functional derivative of IGF-II

9 provided that, if IGF-I or IGF-II is administered an effective
10 amount of NGF or of a functional derivative of NGF is also
11 administered.

1 2. The method of claim 1, wherein there is
2 administered a functional derivative of IGF-I or IGF-II, and
3 said method further comprises administering an effective amount
4 of NGF or a functional derivative thereof.

1 3. The method of claim 1, wherein said neuronal cells
2 are non-mitotic neuronal cells.

1 4. The method of claim 1, wherein said neuronal cells
2 are cholinergic cells.

1 5. The method of claim 1, wherein said method is used
2 for the therapeutic treatment of the deleterious effect of a
3 disease, injury or aging on said neuronal cells.

1 6. The method of claim 5, wherein said disease is
2 Alzheimer's disease, stroke, epilepsy, amyotrophic lateral
3 sclerosis or Parkinson's disease.

1 7. The method of claim 1, wherein at least one of a
2 fragment of IGF-I, a fragment of IGF-II, or a fragment of NGF
3 is administered to said mammal.

- 44 -

1 8. The method of claim 1, wherein said functional
2 derivative of IGF-II is IGF-II(54-67).

1 9. The method of claim 1, wherein at least one of an
2 analog of IGF-I, an analog of a fragment of IGF-I, an analog of
3 IGF-II, an analog of a fragment of IGF-II, an analog of NGF, or
4 an analog of a fragment of NGF is administered to said mammal.

1 10. The method of claim 9, wherein one or more of
2 said analogs administered to said mammal is a polypeptide which
3 has been chemically modified in such a way as to increase its
4 ability to be transported across the blood-brain barrier.

1 11. The method of claim 10, wherein said modification
2 comprises increasing said polypeptide's lipophilicity.

1 12. The method of claim 10, wherein said modification
2 comprises glycosylation.

1 13. The method of claim 10, wherein said modification
2 comprises increasing the net positive charge on said
3 polypeptide.

1 14. The method of claim 1, wherein a combination of
2 two or more of said substances, which act additively, is
3 administered to said mammal.

1 15. The method of claim 1, wherein a combination of
2 two or more of said substances, which act synergistically, is
3 administered to said mammal.

1 16. A method of enhancing the survival of neuronal
2 cells in a mammal, said cells being at risk of dying, said
3 method comprising

- 45 -

4 treating said mammal with a first treatment comprising
5 administration of a cell survival promoting amount of a growth
6 factor, or a functional derivative thereof, and then

7 treating said mammal with a second treatment
8 comprising administration of a nerve transmitter increasing
9 amount of a transmitter enhancer, or a functional derivative
10 thereof.

1 17. The method of claim 16, wherein said second
2 treatment increases the level of a transmitter specific enzyme.

1 18. The method of claim 16, wherein said growth
2 factor is IGF-I or IGF-II.

1 19. The method of claim 16, wherein said functional
2 derivative of said growth factor is a functional derivative of
3 IGF-I or a functional derivative of IGF-II.

1 20. The method of claim 16, wherein said functional
2 derivative of said growth factor comprises a fragment of said
3 growth factor.

1 21. The method of claim 16, wherein said functional
2 derivative of said growth factors is IGF-II(54-67).

1 22. The method of claim 16, wherein said functional
2 derivative of said growth factor comprises any of an analog of
3 said growth factor, or an analog of a fragment of said growth
4 factor.

1 23. The method of claim 22, wherein at least one of
2 said analogs administered to said mammal is a polypeptide which
3 has been chemically modified in such a way as to increase its
4 ability to be transported across the blood-brain barrier.

- 46 -

1 24. The method of claim 23, wherein said modification
2 comprises increasing said polypeptide's lipophilicity.

1 25. The method of claim 23, wherein said modification
2 comprises glycosylation.

1 26. The method of claim 23, wherein said modification
2 comprises increasing the net positive charge on said
3 polypeptide.

1 27. The method of claim 16, wherein said transmitter
2 enhancer is NGF.

1 28. The method of claim 16, wherein said functional
2 derivative of said transmitter enhancer is a functional
3 derivative of NGF.

1 29. The method of claim 16, wherein said functional
2 derivative of said transmitter enhancer comprises a fragment of
3 said transmitter enhancer.

1 30. The method of claim 16, wherein said functional
2 derivative of said transmitter enhancer comprises any of an
3 analog of said transmitter enhancer, or an analog of a fragment
4 of said transmitter enhancer.

1 31. The method of claim 30, wherein at least one of
2 said analogs administered to said mammal is a polypeptide which
3 has been chemically modified in such a way as to increase its
4 ability to be transported across the blood-brain barrier.

1 32. The method of claim 31, wherein said modification
2 comprises increasing said polypeptide's lipophilicity.

- 47 -

1 33. The method of claim 31, wherein said modification
2 comprises glycosylation.

1 34. The method of claim 31, wherein said modification
2 comprises increasing the net positive charge on said
3 polypeptide.

1 35. The method of claim 16, wherein said neuronal
2 cells are non-mitotic neuronal cells.

1 36. The method of claim 16, wherein said neuronal
2 cells are cholinergic cells.

1 37. The method of claim 16, wherein said method is
2 used for the therapeutic treatment of the deleterious effect of
3 a disease, injury or aging on said neuronal cells.

1 38. The method of claim 37, wherein said disease is
2 Alzheimer's disease, stroke, epilepsy, amyotrophic lateral
3 sclerosis or Parkinson's disease.

1 39. The method of claim 16, wherein said first
2 treatment and said second treatment act additively.

1 40. The method of claim 16, wherein said first
2 treatment and said second treatment act synergistically.

1 41. A method of enhancing the cholinergic activity of
2 cholinergic neurons in a mammal, said method comprising
3 administering to said mammal an effective amount of one or more
4 of the following substances:

- 48 -

5 IGF-I;
6 a functional derivative of IGF-I;
7 IGF-II; or
8 a functional derivative of IGF-II
9 provided that if IGF-I or IGF-II is administered NGF or a
10 functional derivative thereof is also administered.

1 42. The method claim 41 wherein there is administered
2 a functional derivative of IGF-I or IGF-II, and said method
3 further comprises administering an effective amount of NGF or a
4 functional derivative thereof.

1 43. The method of claim 41, wherein said method is
2 used for the therapeutic treatment of the deleterious effect of
3 a disease, injury, or aging on said neuronal cells.

1 44. The method of claim 42, wherein said disease is
2 Alzheimer's disease, stroke, epilepsy, amyotrophic lateral
3 sclerosis or Parkinson's disease.

1 45. The method of claim 41, wherein at least one of a
2 fragment of IGF-I, a fragment of IGF-II, or a fragment of NGF
3 is administered to said mammal.

1 46. The method of claim 41, wherein said functional
2 derivative of IGF-II is IGF-II(54-67).

1 47. The method of claim 41, wherein at least one of
2 an analog of IGF-I, an analog of a fragment of IGF-I, an analog
3 of IGF-II, an analog of a fragment of IGF-II, an analog of NGF,
4 or an analog of a fragment of NGF is administered to said
5 mammal.

- 49 -

1 48. The method of claim 47, wherein at least one of
2 said analogs administered to said mammal is a polypeptide which
3 has been chemically modified in such a way as to increase its
4 ability to be transported across the blood-brain barrier.

1 49. The method of claim 48, wherein said modification
2 comprises increasing said polypeptide's lipophilicity.

1 50. The method of claim 48, wherein said modification
2 comprises glycosylation.

1 51. The method of claim 48, wherein said modification
2 comprises increasing the net positive charge on said
3 polypeptide.

1 52. The method of claim 41, wherein a combination of
2 two or more of said substances, which act additively, is
3 administered to said mammal.

1 53. The method of claim 41, wherein a combination of
2 two or more of said substances, which act synergistically, is
3 administered to said mammal.

1 54. A method of enhancing the cholinergic activity of
2 cholinergic neurons in a mammal, said method comprising
3 treating said mammal with a first treatment comprising
4 administration of a cell survival promoting amount of a growth
5 factor, or a functional derivative thereof, and then
6 treating said mammal with a second treatment
7 comprising administration of a nerve transmitter increasing
8 amount of a transmitter enhancer, or a functional derivative
9 thereof.

- 50 -

1 55. The method of claim 54, wherein said second
2 treatment increases the level of a transmitter specific enzyme.

1 56. The method of claim 54, wherein said growth
2 factor is IGF-I or IGF-II.

1 57. The method of claim 54, wherein said functional
2 derivative of said growth factor is a functional derivative of
3 IGF-I or a functional derivative IGF-II.

1 58. The method of claim 54, wherein said functional
2 derivative of said growth factor comprises a fragment of said
3 growth factor.

1 59. The method of claim 58, wherein said functional
2 derivative of said first growth factor is IGF-II(54-67).

1 60. The method of claim 54, wherein said functional
2 derivative of said growth factor comprises any of an analog of
3 said growth factor, or an analog of a fragment of said growth
4 factor.

1 61. The method of claim 60, wherein at least one of
2 said analogs administered to said mammal is a polypeptide which
3 has been chemically modified in such a way as to increase its
4 ability to be transported across the blood-brain barrier.

1 62. The method of claim 61, wherein said modification
2 comprises increasing said polypeptide's lipophilicity.

1 63. The method of claim 61, wherein said modification
2 comprises glycosylation.

- 51 -

1 64. The method of claim 61, wherein said modification
2 comprises increasing the net positive charge on said
3 polypeptide.

1 65. The method of claim 54, wherein said transmitter
2 enhancer is NGF.

1 66. The method of claim 54, wherein said functional
2 derivative of said transmitter enhancer is a functional
3 derivative of NGF.

1 67. The method of claim 54, wherein said functional
2 derivative of said transmitter enhancer comprises a fragment of
3 said transmitter enhancer.

1 68. The method of claim 54, wherein said functional
2 derivative of said transmitter enhancer comprises any of an
3 analog of said transmitter enhancer, or an analog of fragment
4 of said transmitter enhancer.

1 69. The method of claim 68, wherein at least one of
2 said analogs administered to said mammal is a polypeptide which
3 has been chemically modified in such a way as to increase its
4 ability to be transported across the blood-brain barrier.

1 70. The method of claim 69, wherein said modification
2 comprises increasing said polypeptide's lipophilicity.

1 71. The method of claim 69, wherein said modification
2 comprises glycosylation.

1 72. The method of claim 69, wherein said modification
2 comprises increasing the net positive charge on said
3 polypeptide.

- 52 -

1 73. The method of claim 54, wherein said method is
2 used for the therapeutic treatment of the deleterious effect of
3 a disease, injury, or aging on said neuronal cells.

1 74. The method of claim 73, wherein said disease is
2 Alzheimer's disease, stroke, epilepsy, amyotrophic lateral
3 sclerosis or Parkinson's disease.

1 75. The method of claim 54, wherein said first
2 treatment and said second treatment act additively.

1 76. The method of claim 54, wherein said first
2 treatment and said second treatment act synergistically.

1 77. A method of treating a head or spinal cord injury
2 of a mammal, or a disease condition affecting neuronal cells of
3 a mammal, said disease condition comprising stroke, epilepsy,
4 age-related neuronal loss, amyotrophic lateral sclerosis or
5 Parkinson's disease, said method comprising administering to
6 said mammal an effective amount of at least one of the
7 following substances:

8 IGF-I;

9 a functional derivative of IGF-I;

10 IGF-II; or

11 a functional derivative of IGF-II.

1 78. The method of claim 77, wherein an additive
2 combination of two or more of said substances is administered
3 to said mammal.

1 79. The method of claim 77, wherein a synergistic
2 combination of two or more of said substances is administered
3 to said mammal.

- 53 -

1 80. The method of claim 77, wherein said functional
2 derivative of IGF-II is IGF-II(54-67).

1 81. The method of claim 77, further comprising
2 administering an effective amount of NGF or a functional
3 derivative thereof.

1 82. A method of treating a head or spinal cord injury
2 of a mammal, or a disease condition affecting neuronal cells of
3 a mammal, said disease condition comprising stroke, epilepsy,
4 age-related neuronal loss, amyotrophic lateral sclerosis or
5 Parkinson's disease, said method comprising,

6 treating said mammal with a first treatment comprising
7 administration of a cell survival promoting amount of one or
8 more of a group of substances comprising IGF-I, a functional
9 derivative of IGF-I, IGF-II, and a functional derivative of
10 IGF-II, and

11 treating said mammal with a second treatment
12 comprising administration of a nerve transmitter increasing
13 amount of a transmitter enhancer, or a functional derivative
14 thereof.

1 83. The method of claim 82, wherein said transmitter
2 enhancer is NGF, or a functional derivative thereof.

1 84. The method of claim 82, wherein the effect of the
2 administered substances is additive.

1 85. The method of claim 82, wherein the effect of the
2 administered substances is synergistic.

1 86. The method of claim 82, wherein said functional
2 derivative of IGF-II is IGF-II(54-67).

- 54 -

1 87. A method of modifying a ligand capable of binding
2 to a receptor located on a cell surface, said method comprising
3 binding said ligand to a preparation of said receptor
4 prior to subjecting said ligand to a modification procedure,
5 performing said modification procedure, and
6 releasing said ligand from said receptor following
7 said modification procedure.

1 88. The method of claim 87, wherein said ligand is a
2 neuroactive polypeptide.

1 89. The method of claim 87, wherein said modification
2 comprises cationization, glycosylation, or increasing the
3 lipophilicity of the ligand.

1 90. A modified polypeptide made according to the
2 method of claim 87.

1 91. A composition of matter comprising a first
2 component from the group of purified IGF-I, a purified
3 functional derivative of IGF-I, purified IGF-II, or a purified
4 functional derivative of IGF-II, and a second component from
5 the group of purified NGF, or a purified functional derivative
6 of NGF.

1/11





Figure 1


THIS PAGE BLANK (USPTO)

2/11

Effect of IGF-II or IGF-III on Spinal Cord Cholinergic Neuronal Survival**Figure 2**

THIS PAGE BLANK (USPTO)

3/11

Effect of IGF Fragments on Spinal Cord Cholinergic Neuronal Survival**Figure 3**

THIS PAGE BLANK (USPTO)

4/11




Figure 4

THIS PAGE BLANK (USPTO)

5/11




Figure 5

THIS PAGE BLANK (USPTO)

6/11




Figure 6

THIS PAGE BLANK (USPTO)




Fig 7

THIS PAGE BLANK (USPTO)

8/11






Fig 8

THIS PAGE BLANK (USPTO)


9111

Additive effects of NGF and IGF I on choline acetyltransferase activity in cultured rat septal cells



THIS PAGE BLANK (USPTO)

10/11



THIS PAGE BLANK (USPTO)




FIG. 12

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/03166

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): A61K 37/24; A61K 37/26
US. CL.: 424/98; 514/04, 12, 885, 903

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴

Classification System

Classification Symbols

US 424/98; 514/04, 12, 885, 903

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁵

CAS: ON LINE AND APS

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category ⁶	Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	US, A, 4,341,762 (HAAST) 27 July 1982, see the entire document particularly the abstract and column 9, lines 15-27 and examples 1 and 9-12.	1-76, 81-86 and 91
Y	US, A, 4,801,575 (PARDRIDGE) 31 January 1989, abstract and column 2, lines 22-54.	87-90
X Y	EP, A, 0,227,619 (Sara) 01 July 1987, see the entire document, especially the abstract, page 2, lines 24-48 and claims 4-5.	1,3,4 5-9,16,18-22, 35-38,41-47, 54-60,73,74,77 80-83,86 and 91
Y	EP, A, 0,289,314 (Baytink) 02 November 1988, see page 3, lines 37-47.	8-10,12,19-23, 25,45-48,50, 57-60,63 and 91

⁶ Special categories of cited documents: ¹³

"A" document defining the general state of the art which is not
considered to be of particular relevance

"E" earlier document but published on or after the international
filing date

"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or
other means

"P" document published prior to the international filing date but
later than the priority date claimed

"T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

"X" document of particular relevance; the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step

"Y" document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ²

28 August 1990

Date of Mailing of this International Search Report ³

24 SEP 1990

International Searching Authority ¹

ISA/US

Signature of Authorized Officer ¹⁰

Fateme Moezie
Fateme Moezie

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

	Pharmacology Biochemistry & Behavior, Vol. 11, issued 1979, Kastin, et al., "Analgesia After Peripheral Administration of Enkephalin and Endorphin Analogues" Discussion, pages 715-716, especially 2nd and 3rd paragraphs.	10,11,23,24,31, 32,48,49,61,62, 69,70
--	--	---

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out², specifically:

3. ☐ Claim numbers _____ because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁰ with indication, where appropriate, of the relevant passages ¹¹	Relevant to Claim No ¹²
X Y	Acta. Physiol. Scand. Vol. 126, issued 1986, H.A. HANSSON et al. "Evidence indicating trophic importance of IGF-I in regenerating peripheral nerves" see paragraph bridging pages 613 and 614.	<u>77</u> 82
Y	Brain Research, Vol. 485, issued 1989, J. Sjöberg "Insulin-like growth factor (IGF-1) as a stimulator of regeneration in freeze-injured rat sciatic nerve", see abstract at page 102.	<u>77</u> 82
A	The Merck Index, Ninth edition, published 1976 by Merck and Co., Inc. See entry no. 6306 "NGF" at page 843.	1-91
Y	WO, A, 89/01343 (PARDRIDGE et al.) 23 February 1989, see the entire document, particularly the abstract.	10,13,23,26,31, 34,48,51,61,64, 69,72

THIS PAGE BLANK (USPTO)